Literature DB >> 24338377

High expression of CXCR-2 correlates with lymph node metastasis and predicts unfavorable prognosis in resected esophageal carcinoma.

Ping Sui1, Pingping Hu, Tiehong Zhang, Xiangwei Zhang, Qi Liu, Jiajun Du.   

Abstract

CXC chemokines have been reported to play critical roles in tumor growth, angiogenesis, invasion and metastasis of various human cancers. However, expression of CXC chemokines type 2 (CXCR2) and its association with clinicopathological characters and patients' prognosis in esophageal cancer are scarcely reported. We retrospectively collected clinicopathologic characteristics of 95 esophageal cancer patients undergoing esophagectomies. Immunohistochemistry was used to detect the expression of CXCR2. The survival was analyzed by the Kaplan-Meier method. Univariate and multivariate analyses were then performed to determine the relationship between CXCR2 and the clinical characteristics and to analyze whether CXCR2 expression was a significant independent prognostic factor for esophageal cancer patients. CXCR2 was highly expressed in 57.9 % of the randomly selected specimens. The expression of CXCR2 was significantly related to lymph node metastasis (P = 0.044) and predicted poor overall status in operable esophageal cancer patients (P = 0.012). Cox proportional hazard analysis regression analysis indicated that CXCR2 expression (P = 0.030) and lymphatic metastasis (P < 0.001) may serve as independent prognostic markers for esophageal cancer patients. Our results demonstrate that CXCR2 significantly correlates with lymph node metastasis and is a poor prognostic factor in resected esophageal squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24338377     DOI: 10.1007/s12032-013-0809-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

Review 1.  Current status of chemokine receptor inhibitors in development.

Authors:  Marcello Allegretti; Maria Candida Cesta; Alexandre Garin; Amanda E I Proudfoot
Journal:  Immunol Lett       Date:  2012-04-20       Impact factor: 3.685

2.  Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.

Authors:  Michelle L Varney; Seema Singh; Aihua Li; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Cancer Lett       Date:  2010-10-29       Impact factor: 8.679

Review 3.  Chemokines as mediators of tumor angiogenesis and neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Exp Cell Res       Date:  2010-10-30       Impact factor: 3.905

Review 4.  Chemokines as targets for therapy.

Authors:  Alexandre Garin; Amanda E I Proudfoot
Journal:  Exp Cell Res       Date:  2011-03-10       Impact factor: 3.905

Review 5.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

6.  Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis.

Authors:  Moritz N Wente; Michael P Keane; Marie D Burdick; Helmut Friess; Markus W Büchler; Güralp O Ceyhan; Howard A Reber; Robert M Strieter; Oscar J Hines
Journal:  Cancer Lett       Date:  2006-02-03       Impact factor: 8.679

7.  Chemokine research moves on.

Authors:  Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-15       Impact factor: 3.905

8.  Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Authors:  Seema Singh; Anguraj Sadanandam; Kalyan C Nannuru; Michelle L Varney; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

9.  Arrestin regulates MAPK activation and prevents NADPH oxidase-dependent death of cells expressing CXCR2.

Authors:  Ming Zhao; Antonia Wimmer; Khanh Trieu; Richard G Discipio; Ingrid U Schraufstatter
Journal:  J Biol Chem       Date:  2004-09-13       Impact factor: 5.157

10.  Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer.

Authors:  Hideaki Ijichi
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

View more
  20 in total

Review 1.  Chemokines and their receptors as biomarkers in esophageal cancer.

Authors:  Masakazu Goto; Mingyao Liu
Journal:  Esophagus       Date:  2019-11-26       Impact factor: 4.230

2.  CXCL12 chemokine expression suppresses human breast cancer growth and metastasis in vitro and in vivo.

Authors:  Zhi-Dong Lv; Bin Kong; Xiang-Ping Liu; Qian Dong; Hai-Tao Niu; Yong-Hua Wang; Fu-Nian Li; Hai-Bo Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 3.  Chemokines and their receptors in esophageal cancer--the systematic review and future perspectives.

Authors:  Marta Łukaszewicz-Zając; Barbara Mroczko; Maciej Szmitkowski
Journal:  Tumour Biol       Date:  2015-07-01

Review 4.  Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis.

Authors:  Simona L Schlereth; Nasrin Refaian; Sandra Iden; Claus Cursiefen; Ludwig M Heindl
Journal:  Biomed Res Int       Date:  2014-09-01       Impact factor: 3.411

Review 5.  The role of chemoattractant receptors in shaping the tumor microenvironment.

Authors:  Jiamin Zhou; Yi Xiang; Teizo Yoshimura; Keqiang Chen; Wanghua Gong; Jian Huang; Ye Zhou; Xiaohong Yao; Xiuwu Bian; Ji Ming Wang
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

6.  miR-940 Suppresses Tumor Cell Invasion and Migration via Regulation of CXCR2 in Hepatocellular Carcinoma.

Authors:  Dong Ding; Yaodong Zhang; Renjie Yang; Xing Wang; Guwei Ji; Liqun Huo; Zicheng Shao; Xiangcheng Li
Journal:  Biomed Res Int       Date:  2016-10-11       Impact factor: 3.411

7.  CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells.

Authors:  Masayoshi Hosono; Yu-Ichiro Koma; Nobuhisa Takase; Naoki Urakawa; Nobuhide Higashino; Kazuki Suemune; Himiko Kodaira; Mari Nishio; Manabu Shigeoka; Yoshihiro Kakeji; Hiroshi Yokozaki
Journal:  Oncotarget       Date:  2017-11-20

8.  The prognostic value of CXC chemokine receptor 2 (CXCR2) in cancers: a meta-analysis.

Authors:  Bingbing Qiao; Wenqin Luo; Yanna Liu; Jing Wang; Chuan Liu; Zhao Liu; Sizhe Chen; Jingjing Gu; Xiaolong Qi; Tongwei Wu
Journal:  Oncotarget       Date:  2017-12-11

9.  CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma.

Authors:  Li Li; Li Xu; Jing Yan; Zuo-Jun Zhen; Yong Ji; Chao-Qun Liu; Wan Yee Lau; Limin Zheng; Jing Xu
Journal:  J Exp Clin Cancer Res       Date:  2015-10-26

10.  The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients.

Authors:  Zhenglin Wang; Hao Liu; Zhenbin Shen; Xuefei Wang; Heng Zhang; Jing Qin; Jiejie Xu; Yihong Sun; Xinyu Qin
Journal:  BMC Cancer       Date:  2015-10-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.